Daniel Cher, MD
About Daniel Cher, MD
Daniel Cher, MD, serves as the Senior Vice President of Clinical and Regulatory Affairs at SI-BONE, where he has worked since 2021. He has extensive experience in clinical affairs and regulatory submissions for medical devices, with a strong background in statistics and a medical degree from Yale School of Medicine.
Current Role at SI-BONE
Daniel Cher serves as the Senior Vice President of Clinical and Regulatory Affairs at SI-BONE, a position he has held since 2021. In this role, he oversees clinical and regulatory strategies, contributing to the development and approval of medical devices. His leadership is instrumental in navigating complex regulatory environments and ensuring compliance with industry standards.
Previous Experience at SI-BONE
Prior to his current role, Daniel Cher worked at SI-BONE as the Vice President of Clinical Affairs from 2012 to 2021. During his nine years in this position, he played a key role in advancing clinical research initiatives and enhancing the company's product offerings in the medical device sector.
Background in Medical Affairs
Daniel Cher has extensive experience in medical affairs, having served as Vice President of Medical Affairs and Head of Biostatistics at Procept BioRobotics from 2018 to 2021. His background includes significant contributions to the success of class II and III medical devices, showcasing his expertise in biostatistics and regulatory submissions.
Education and Qualifications
Daniel Cher earned his Doctor of Medicine (M.D.) from the Yale School of Medicine, completing his studies from 1986 to 1990. He also holds a Bachelor of Science in Biology from Stanford University, where he studied from 1982 to 1986. His educational background provides a strong foundation for his work in clinical and regulatory affairs.
Achievements in Regulatory Affairs
Throughout his career, Daniel Cher has led clinical and regulatory strategies that resulted in two breakthrough device designations and EU MDR certification for sacroiliac joint fusion and pelvic fixation devices. His expertise as a primary statistician on several regulatory submissions, including four PMAs and multiple 510ks, underscores his significant contributions to the field.